Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Leukemic stem cells (LSCs) in chronic myeloid leukemia are resistant to imatinib and therefore are a cause of relapse. The authors show that IRAK1/4-NF-κB-PD-L1 signaling is critical to mediate imatinib resistance in LSCs and that combining imatinib with blocking this signalling pathway can eliminat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-27928-8 |
| _version_ | 1798026531150233600 |
|---|---|
| author | Yosuke Tanaka Reina Takeda Tsuyoshi Fukushima Keiko Mikami Shun Tsuchiya Moe Tamura Keito Adachi Terumasa Umemoto Shuhei Asada Naoki Watanabe Soji Morishita Misa Imai Masayoshi Nagata Marito Araki Hitoshi Takizawa Tomofusa Fukuyama Chrystelle Lamagna Esteban S. Masuda Ryoji Ito Susumu Goyama Norio Komatsu Tomoiku Takaku Toshio Kitamura |
| author_facet | Yosuke Tanaka Reina Takeda Tsuyoshi Fukushima Keiko Mikami Shun Tsuchiya Moe Tamura Keito Adachi Terumasa Umemoto Shuhei Asada Naoki Watanabe Soji Morishita Misa Imai Masayoshi Nagata Marito Araki Hitoshi Takizawa Tomofusa Fukuyama Chrystelle Lamagna Esteban S. Masuda Ryoji Ito Susumu Goyama Norio Komatsu Tomoiku Takaku Toshio Kitamura |
| author_sort | Yosuke Tanaka |
| collection | DOAJ |
| description | Leukemic stem cells (LSCs) in chronic myeloid leukemia are resistant to imatinib and therefore are a cause of relapse. The authors show that IRAK1/4-NF-κB-PD-L1 signaling is critical to mediate imatinib resistance in LSCs and that combining imatinib with blocking this signalling pathway can eliminate LSCs. |
| first_indexed | 2024-04-11T18:36:47Z |
| format | Article |
| id | doaj.art-c3477c962caf480e9537b3db7eabd49c |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-11T18:36:47Z |
| publishDate | 2022-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-c3477c962caf480e9537b3db7eabd49c2022-12-22T04:09:15ZengNature PortfolioNature Communications2041-17232022-01-0113111310.1038/s41467-021-27928-8Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitorsYosuke Tanaka0Reina Takeda1Tsuyoshi Fukushima2Keiko Mikami3Shun Tsuchiya4Moe Tamura5Keito Adachi6Terumasa Umemoto7Shuhei Asada8Naoki Watanabe9Soji Morishita10Misa Imai11Masayoshi Nagata12Marito Araki13Hitoshi Takizawa14Tomofusa Fukuyama15Chrystelle Lamagna16Esteban S. Masuda17Ryoji Ito18Susumu Goyama19Norio Komatsu20Tomoiku Takaku21Toshio Kitamura22Division of Cellular Therapy, The Institute of Medical Science, The University of TokyoDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoDepartment of Hematology, Juntendo University Graduate School of MedicineDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoInternational Research Center for Medical Sciences, Kumamoto UniversityDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of MedicineDepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of MedicineDepartment of Urology, Juntendo University Graduate School of MedicineDepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of MedicineInternational Research Center for Medical Sciences, Kumamoto UniversityDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoRigel, South San FranciscoRigel, South San FranciscoCentral Institute for Experimental AnimalsDivision of Molecular Oncology Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of TokyoDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Hematology, Juntendo University Graduate School of MedicineDivision of Cellular Therapy, The Institute of Medical Science, The University of TokyoLeukemic stem cells (LSCs) in chronic myeloid leukemia are resistant to imatinib and therefore are a cause of relapse. The authors show that IRAK1/4-NF-κB-PD-L1 signaling is critical to mediate imatinib resistance in LSCs and that combining imatinib with blocking this signalling pathway can eliminate LSCs.https://doi.org/10.1038/s41467-021-27928-8 |
| spellingShingle | Yosuke Tanaka Reina Takeda Tsuyoshi Fukushima Keiko Mikami Shun Tsuchiya Moe Tamura Keito Adachi Terumasa Umemoto Shuhei Asada Naoki Watanabe Soji Morishita Misa Imai Masayoshi Nagata Marito Araki Hitoshi Takizawa Tomofusa Fukuyama Chrystelle Lamagna Esteban S. Masuda Ryoji Ito Susumu Goyama Norio Komatsu Tomoiku Takaku Toshio Kitamura Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors Nature Communications |
| title | Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors |
| title_full | Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors |
| title_fullStr | Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors |
| title_full_unstemmed | Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors |
| title_short | Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors |
| title_sort | eliminating chronic myeloid leukemia stem cells by irak1 4 inhibitors |
| url | https://doi.org/10.1038/s41467-021-27928-8 |
| work_keys_str_mv | AT yosuketanaka eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT reinatakeda eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT tsuyoshifukushima eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT keikomikami eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT shuntsuchiya eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT moetamura eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT keitoadachi eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT terumasaumemoto eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT shuheiasada eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT naokiwatanabe eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT sojimorishita eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT misaimai eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT masayoshinagata eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT maritoaraki eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT hitoshitakizawa eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT tomofusafukuyama eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT chrystellelamagna eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT estebansmasuda eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT ryojiito eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT susumugoyama eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT noriokomatsu eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT tomoikutakaku eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors AT toshiokitamura eliminatingchronicmyeloidleukemiastemcellsbyirak14inhibitors |